Literature DB >> 27926715

Despite slow progress, bispecifics generate buzz.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27926715     DOI： 10.1038/nbt1216-1215

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Amgen swallows Micromet to BiTE into ALL market.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-04-10       Impact factor: 54.908

2.  Amgen's bispecific antibody puffs across finish line.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-03       Impact factor: 54.908
  2 in total
  10 in total

1.  Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.

Authors:  Shiyong Gong; Fang Ren; Danqing Wu; Xuan Wu; Chengbin Wu
Journal:  MAbs       Date:  2017-07-10       Impact factor: 5.857

2.  A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.

Authors:  Michael Lyman; Vincent Lieuw; Robyn Richardson; Anjuli Timmer; Christine Stewart; Steve Granger; Richard Woods; Michela Silacci; Dragan Grabulovski; Roland Newman
Journal:  J Biol Chem       Date:  2018-04-20       Impact factor: 5.157

3.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

Review 4.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 5.  Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Authors:  Daniel G Guy; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

6.  Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.

Authors:  Darko Skegro; Cian Stutz; Romain Ollier; Emelie Svensson; Paul Wassmann; Florence Bourquin; Thierry Monney; Sunitha Gn; Stanislas Blein
Journal:  J Biol Chem       Date:  2017-04-27       Impact factor: 5.157

Review 7.  Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.

Authors:  A Trivedi; S Stienen; M Zhu; H Li; T Yuraszeck; J Gibbs; T Heath; R Loberg; S Kasichayanula
Journal:  Clin Transl Sci       Date:  2017-03-15       Impact factor: 4.689

8.  Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development.

Authors:  Romain Ollier; Paul Wassmann; Thierry Monney; Christelle Ries Fecourt; Sunitha Gn; Vinu C A; Daniel Ayoub; Cian Stutz; Girish S Gudi; Stanislas Blein
Journal:  MAbs       Date:  2019-09-12       Impact factor: 5.857

Review 9.  Redirecting T cells to hematological malignancies with bispecific antibodies.

Authors:  Mireya Paulina Velasquez; Challice L Bonifant; Stephen Gottschalk
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

Review 10.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.